Euraly Announces Publication In Acta Neuropathologica Communications Of Preclinical Data Detailing The Neuroprotective Effect Nly01 Models Alzheimers Disease News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Apr 28, 2021
 
Neuronal viability was preserved, resulting in improved spatial learning and memory
 
GAITHERSBURG, Md. (BUSINESS WIRE) Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced publication in the peer-reviewed journal
Acta Neuropathologica Communications of preclinical data that contributed to the therapeutic rationale for clinical evaluation of NLY01 in Alzheimer’s and Parkinson’s diseases. The research was conducted in collaboration with Dr. Ted Dawson’s lab at the Johns Hopkins School of Medicine.
The publication, entitled “Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer’s disease” demonstrated that NLY01, an engineered exendin-4, glucagon-like peptide-1 receptor (GLP-1R) agonist, can selectively block β-amyloid-induced activation of microglia through upregulated GLP-1R, inhibit format ....

Seulki Lee , Viktor Roschke , Ted Dawson , Acta Neuropathologica Communications , Johns Hopkins School Of Medicine , Johns Hopkins School , Chief Executive Officer , Nature Medicine , Chief Scientific Officer , Euraly Announces Publication In Acta Neuropathologica Communications Of Preclinical Data Detailing The Neuroprotective Effect Nly01 Models Alzheimers Disease , டெட் டாசன் , ஜான்ஸ் ஹாப்கின்ஸ் பள்ளி ஆஃப் மருந்து , ஜான்ஸ் ஹாப்கின்ஸ் பள்ளி , தலைமை நிர்வாகி அதிகாரி , இயற்கை மருந்து , தலைமை அறிவியல் அதிகாரி ,